AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02223767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Sham TMS
Description: Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
Study NCT00853177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MEOPA inhalation
Description: N2O of 50% and 50% O2
Study NCT00853177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: xylocaine
Description: Ampoule-bottle of 20 ml
Study NCT04197570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Anesthetics
Description: see arm/group description
Study NCT04197570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non Opioid Analgesics
Description: see arm/group description
Study NCT00613028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temo + Avastin
Description: Patients have progressed/had gr3/> toxicity related to etoposide, with no had progression/gr 3/> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
Study NCT00613028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16 + Avastin
Description: Patients have progressed/had gr3/> toxicity related to temozolomide, but have not progressed/gr3/> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
Study NCT03672435 — intervention group
Intervention type: DRUG
Intervention: Topical Solution
Description: proparacaine 0.5% eye drop
Study NCT03732053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GPR Intervention Research group
Description: The research intervention consisted in the reappointment of three GPR therapeutic postures.
Study NCT01070225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone/ Placebo and Propranolol
Description: Hydrocortisone 400mcg Propranolol 10mg or 20 mg
Study NCT01070225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone/ Placebo and Propranolol
Description: Hydrocortisone 400mcg Propranolol 10mg or 20 mg
Study NCT00625846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04411342 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Albumin creatinine ratio
Description: normal range of albumin in urine in patients with type 2 diabetes
Study NCT00625846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT01040468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass surgery
Description: Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
Study NCT01040468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Adjustable Gastric Banding surgery
Description: Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
Study NCT01040468 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Lifestyle Modification
Description: Intensive lifestyle modification program for weight loss. Participants randomized to this condition will receive an weekly individual treatment of 30 minutes for the first 6 months and every-other-week sessions from months 7 to 12. Treatment will be provided by a behavioral psychologist or registered dietitian following a structured curriculum used in our prior studies. During the first 4 months, participants will be prescribed a 1000-1200 kcal/d diet that provides four daily servings of meal replacement products (liquid shakes, cereals, meal bars, etc), combined with an evening dinner entree. Each serving of the meal replacement (HMR 170; Boston, MA) will provide 170 calories, with 16 g of protein, 22 g of carbohydrate, and 2 g of fat. Dinner entrees (containing at least 20 g of protein and approximately 220-260 kcal) will be consumed with a garden salad and a serving of fruit (and other vegetables allowed ad libitum throughout the day).
Study NCT01902992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depiquick Birch (DPG103)
Study NCT01902992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02881294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUVN-G3031
Study NCT03253159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room.
Study NCT00589966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training
Description: Coping Skills Training teaches skills for managing physical, emotional, and social challenges of symptoms commonly experienced by men who have undergone treatment for early stage prostate cancer. Coping skills include activity pacing, managing negative mood, communication enhancement, and applied relaxation.
Study NCT00589966 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prostate Cancer Education
Description: Prostate Cancer Education provides information on the following topics: common treatment side-effects, medical options for symptom management, nutrition to support recovery, and guidelines for communicating with your healthcare team.
Study NCT05531695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise (either aerobic or flexibility)
Study NCT05531695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise (either aerobic or flexibility)
Study NCT02724176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbon nanoparticles
Description: 0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
Study NCT03730025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auscultation plus NeoTapAS
Description: Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
Study NCT03730025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auscultation without NeoTapAS
Description: Auscultation without NeoTapAS
Study NCT03901339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously
Study NCT03901339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Administered intravenously per NCCN guidelines
Study NCT04334304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted Total Knee Arthroplasty
Description: A total knee arthroplasty will be performed with robot-assistance (NAVIO).
Study NCT04334304 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Prosthesis - type Posterior Stabilized
Description: A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
Study NCT04334304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Prosthesis - type Posterior Stabilized
Description: A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
Study NCT03776799 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stent-avoiding
Description: Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
Study NCT03776799 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stent-based
Description: Stenting, in which a stent is advanced and implanted in the obstructed artery, has become the standard endovascular treatment for peripheral arteries
Study NCT02293798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silk surgical scaffold
Description: surgical implant
Study NCT00825201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IP
Study NCT00825201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Description: Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
Study NCT00825201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
Study NCT00825201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
Study NCT00825201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT05543902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Problems Management Model (BPMM)
Description: The BPMM was composed of interventions with the leadership of a nurse and included topics of the early postpartum period; postpartum 1st, 2nd, 6th, and 8th weeks; increasing breastfeeding motivation and breastfeeding success; and preventing and eliminating breastfeeding problems. The components of the model included meeting women face-to-face, giving education using a booklet, providing breastfeeding consultancy on the phone, and home visits.
Study NCT03117816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOP2014 / Pegylated-Proline-interferon alpha-2b
Description: AOP2014 as pre-filled auto-injection pen for subcutaneous injection, containing 250 µg AOP2014 / 0.5 ml. The solution also contains inactive ingredients (sodium chloride, polysorbate 80, benzyl alcohol, sodium acetate, and acetic acid). The solution is colorless to light yellow.
Study NCT03117816 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surveillance
Description: For patients randomized into this treatment arm stopp their standard treatment and will just be under observation.
Study NCT02195375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutiform 500/20 µg BID
Study NCT02195375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutiform 250/10 µg BID
Study NCT02195375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Accuhaler 50/500 µg BID
Study NCT02624440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard myeloma treatment
Description: The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma
Study NCT02624440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: P.o. clarithromycin 250 mg twice daily
Study NCT02624440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole/trimethoprim
Description: P.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily
Study NCT02624440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Observation
Description: Observation without prophylactic antibiotic
Study NCT01722539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Description: Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more
Study NCT01722539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine
Description: Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.
Study NCT01722539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
Study NCT01722539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
Study NCT01722539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.
Study NCT01722539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.
Study NCT03044366 — intervention group
Intervention type: OTHER
Intervention: general anesthesia management of preterm infants
Description: general anesthesia management of preterm infants
Study NCT00867165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: oral tablets: ezetimibe 10 mg once daily for 12 weeks
Study NCT03901339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered orally per NCCN guidelines
Study NCT03901339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered intravenously per NCCN guidelines
Study NCT03901339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Administered intravenously per NCCN guidelines
Study NCT01369836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumin
Description: A single oral dose of 20 mg capsule
Study NCT01369836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumin
Description: A single oral dose of 40 mg capsule.
Study NCT01369836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A single oral dose of matched placebo.
Study NCT00867165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period
Study NCT01077791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: original cognitive therapy
Description: 12 weekly sequences of an original cognitive therapy based on videos involving the learning of a better use of contextual information to infer others' intention. Group of 5 patients trained by 2 therapeutics. Comparison with a non-cognitive psychoeducational training (same organisational design).
Study NCT02525380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device(DC Bead)
Description: Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system
Study NCT02348593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110
Study NCT02348593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Study NCT02744365 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: All women of the biobank have provided:~1. blood samples (plasma, serum and Buffy-coat)~2. urine samples~3. demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history)~4. mean arterial blood pressure~5. ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases)~6. access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)
Study NCT04140461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B
Description: The trial group and the control group received AmB 0.5mg/kg for 4 weeks and 0.7mg/kg for 2 weeks respectively.
Study NCT04140461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Description: The trial group and the control group received AmB 0.5mg/kg for 4 weeks and 0.7mg/kg for 2 weeks respectively.
Study NCT04140461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucytosine
Description: The trial group and the control group received 100mg/kg for 4 weeks and for 2 weeks respectively.
Study NCT04140461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucytosine
Description: The trial group and the control group received 100mg/kg for 4 weeks and for 2 weeks respectively.
Study NCT03270917 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Parenchymal preserving postero-superior liver segment resection
Description: Parenchymal preserving liver segment resection of one or two of the postero-superior liver segments (4A, 7 or 8).
Study NCT02965352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Door handle device
Description: To evaluate the cylindrical grip movement, it was used a door handle, which evaluated all the strength at the arc of motion
Study NCT04138992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab will be used during neoadjuvant and concurrent chemoradiotherapy
Study NCT02965352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linear switch device
Description: To evaluate the pulp-pulp pinch movement, it was used one linear switch, which evaluated all the strength at the motion displacement.
Study NCT02965352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Door key device
Description: To evaluate the pulp-side pinch movement, it was used a door key, which evaluated all the strength at the arc of motion
Study NCT03676400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conditioned media of umbilical cord blood-derived stem cells
Description: Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
Study NCT03676400 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells
Study NCT03270046 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Water enema
Description: Addition of water enema in standard PEG preparation in participants scheduled for CRC screening.
Study NCT02712736 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: quality of life survey
Description: subjects with PSC will be administered a survey to assess their quality of life
Study NCT02663999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diazepam nasal spray
Description: diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
Study NCT01421524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are > 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).
Study NCT01421524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.
Study NCT01421524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .